Skip to main content

Table 1 Profile of HAM/TSP patients enrolled and improvement of motor function in the lower extremities 12 weeks after treatment

From: Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial

  Age (years) Sex Duration of illuness (years) Concomitant therapy Intermittent self-catheterization OMDSa Spasticity of the lower extremities
Case no.     Immunomodulator Drug for neurogenic bladder     
      Anticholinergic α1 blocker   Before treatment After treatment Before treatment Improvementb
1 80 Female 23 No Yes   Yes 6 6 Yes Yes
2 64 Female 16 No Yes   Yes 6 6 Yes Yes
3 57 Male 51 PSL/ IFN-α Yes   Yes 6 6 Yes Yes
4 51 Female 36 No Yes   Yes 9 9 Yes Yes
5 67 Female 3 No    Yes 3 3 No  
6 61 Female 30 No    Yes 5 5 Yes Yes
7 68 Female 12 No   Yes No 4 4 Yes Yes
8 64 Male 11 PSL   Yes No 5 5 Yes No
9 66 Male 23 PSL Yes   Yes 9 9 Yes Yes
10 76 Male 23 No    No 6 6 Yes Yes
11 53 Female 7 No    Yes 6 6 Yes No
12 62 Female 12 PSL   Yes Yes 4 4 No  
13 44 Female 22 No    Yes 6 6 Yes No
14 56 Male 10 No Yes   Yes 5 5 Yes Yes
15 71 Female 45 No Yes   Yes 9 9 No  
16 78 Female 18 No Yes   Yes 5 5 Yes Yes
17 50 Female 19 No    No 5 5 Yes Yes
18 63 Female 29 No Yes   Yes 8 8 Yes Yes
19 62 Female 9 PSL Yes   Yes 8 8 Yes No
20 60 Female 34 No Yes   Yes 2 1 No  
21 46 Female 26 PSL   Yes No 2 1 Yes Yes
22 31 Female 7 No   Yes No 4 3 Yes Yes
23 56 Male 18 No    Yes 10 10 No  
24 56 Male 16 IFN-α    No 2 2 Yes Yes
Remarks mean ± SD;   mean ± SD;         % improvement:
  60.1 ± 11.2   20.9 ± 12.1         78.9 (P = 0.0003)c
  1. aOsame’s motor function score (OMDS) was rated from 0 to 13 according to the disability grade [13].
  2. bImprovement in spasticity of more than 1 grade according to the modifiedAshworth scale [14].
  3. cStatistical significance was determined by the McNemar test.
  4. IFNα interferon α, PSL prednisolone.